Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
January 25, 2023
Precigen (PGEN) $75 M offering priced at $1.75
January 24, 2023
Verastem Oncology (VSTM) $60 M Private Placement Offering of Series B Convertible Preferred Stock
January 18, 2023
bluebird bio (BLUE) prices offering of 20 M shares at $6.00
January 9, 2023
RegMed Investors (RMi) Research Note: News related to JPM23
January 2, 2023
RegMed investors (RMi) Research Note: Agenus (AGEN) possible offering of 1.95 million share
December 1, 2022
RegMed investors (RMi) Research Note: Intellia Therapeutics (NTLA) prices offering of 6.25 million shares priced at $45.80
November 15, 2022
RegMed Investors (RMi) Research Note: Applied Genetic Technologies (AGTC)
November 7, 2022
Verve Therapeutics (VERV -$8.02 or -19.08% to $23.27) crashes after FDA halts IND to test gene editor Ion patients
November 2, 2022
Compass Therapeutics (CMPX) files for a private investment in public equity (PIPE) financing to raise $80 million
October 28, 2022
RegMed Investors (RMi): Research Note: Solid Biosciences (SLDB) announces a 1-for-15 Reverse Stock Split
October 25, 2022
Syncona (SYNC) to acquire Applied Genetic Technologies Corporation (AGTC) update
October 20, 2022
Prime Medicine (PRME) a gene editing company has raised $175 million selling 1.4 million shares in the middle of its $17-$19 price range in its IPO
October 19, 2022
Avrobio (AVRO) received De-Listing Notice for being under $1.00 compliance with Nasdaq, has 180 days to correct
September 30, 2022
Solid Biosciences (SLDB) announces acquisition of Aavanti Bio Inc (private)and concurrent $75 Million Private Placement
September 28, 2022
RegMed Investors’ (RMi): What’s up Applied Genetic Technologies (AGTC)?
September 16, 2022
The Biostage (BSTG) Chronicles: Who is or what is behind the purchases and pump/promote of BSTG’s volume and share pricing?
August 30, 2022
RegMed Investors (RMI): burning investors, Applied Genetic Technologies (AGTC)
August 16, 2022
RegMed Investors’ (RMI) Earnings: dates of releases and more results
July 21, 2022
Verve Therapeutics (VERV) proposes $200 M offering priced at $27.00
July 13, 2022
Applied Genetic Technologies (AGTC) prices public offering of 16,66 M shares at $0.60
June 23, 2022
The Biostage (BSTG) Chronicles: filed an S-1 preliminary offering prospectus by Newbridge Securities Corporation.
June 2, 2022
Chinook Therapeutics (KDNY) public offering of 6,4 M shares priced at $14.00 raising $105 M
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.